Correction of the tumor suppressor Salvador homolog-1 deficiency in tumors by lycorine as a new strategy in lung cancer therapy.

MLA

Zhao, Zhe, et al. “Correction of the Tumor Suppressor Salvador Homolog-1 Deficiency in Tumors by Lycorine as a New Strategy in Lung Cancer Therapy.” Cell Death & Disease, vol. 11, no. 5, May 2020, pp. 1–14. EBSCOhost, https://doi.org/10.1038/s41419-020-2591-0.

APA

Zhao, Z., Xiang, S., Qi, J., Wei, Y., Zhang, M., Yao, J., Zhang, T., Meng, M., Wang, X., & Zhou, Q. (2020). Correction of the tumor suppressor Salvador homolog-1 deficiency in tumors by lycorine as a new strategy in lung cancer therapy. Cell Death & Disease, 11(5), 1–14. https://doi.org/10.1038/s41419-020-2591-0

Chicago

Zhao, Zhe, Shufen Xiang, Jindan Qi, Yijun Wei, Mengli Zhang, Jun Yao, Tong Zhang, Mei Meng, Xiaohua Wang, and Quansheng Zhou. 2020. “Correction of the Tumor Suppressor Salvador Homolog-1 Deficiency in Tumors by Lycorine as a New Strategy in Lung Cancer Therapy.” Cell Death & Disease 11 (5): 1–14. doi:10.1038/s41419-020-2591-0.